Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical - Seite 4

Nachrichtenquelle: globenewswire
25.09.2020, 13:00  |  123   |   |   

Diesen Artikel teilen
Seite 4 von 3

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical - Seite 4 Japan is the first country to approve sofpironium bromide with commercial launch expected later this year Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in Q4 2020 BOULDER, Colo., Sept. 25, 2020 (GLOBE …

Nachrichten des Autors

Titel
Titel
Titel
Titel